HCG Share Price: Cancer care network badhane ke liye **₹424 Cr** ka Rights Issue! Kya hai plan?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
HCG Share Price: Cancer care network badhane ke liye **₹424 Cr** ka Rights Issue! Kya hai plan?
Overview

Chalo, HCG ke investors ke liye ek badi khabar hai! Company ne apka cancer care network aur badhane ke liye **₹424.68 crore** ka Rights Issue announce kiya hai. Ye paisa KKR ke majority acquisition ke baad aya hai aur company ko India mein sabse bada cancer care network banane mein help karega.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

KKR ke baad ab HCG ka naya plan!

Is capital infusion ke saath, HCG apne growth plans ko aur tezi se aage badhana chahta hai, khaas kar jab KKR jaise bade investors jud gaye hain. India mein specialized healthcare market badh raha hai aur HCG ko iska fayda uthana hai. Ye rights issue company ko competition mein aage rehne aur apni services ko behtar banane mein madad karega.

Fund raising se expansion ka raasta

HCG ne 10 April, 2026 ko ₹424.68 crore ka rights issue announce kiya hai. Isse cancer care facilities ko expand karne aur latest treatments ko integrate karne mein help milegi. Stock ki baat karein toh pichle 6 mahine mein yeh 20.18% gira hai aur 8 April, 2026 tak lagbhag ₹544.65 par trade kar raha tha. Company ki market cap abhi ₹82.55 billion ke aas paas hai.

Oncology market mein HCG ka leadership

India mein oncology market tezi se badh raha hai. 2025 se 2030 tak iske 20% annually grow hone ka andaaza hai, jo lagbhag $2.36 billion add kar sakta hai. HCG already India ke sabse bade cancer care network ko manage karta hai, jisme 21 dedicated centers hain. Ye rights issue KKR ke early 2025 mein majority acquisition ke baad aya hai. Cyril Amarchand Mangaldas HCG ko legal advice de raha hai.

Challenges aur future outlook

Bade market share ke bawajood, HCG ko kuch challenges face karne pad rahe hain. Company ka P/E ratio 350x se zyada hai, jo high market expectations dikhata hai. Q3FY26 mein company ne Net Loss report kiya tha, mostly exceptional costs ki wajah se. Expansion aur acquisitions mein heavy investment ke karan debt-to-equity ratio 0.85 aur Net Debt/EBITDA ratio 4.33 hai. Analysts ka kehna hai ki earnings per share estimates mein kami aa sakti hai.

Management ka target hai ki aane wale 3-4 saalon mein 15%+ annual revenue growth aur 23-24% EBITDA margins achieve karein. North Bangalore mein ek naya hospital Q4FY26 tak khulne wala hai. Analysts ka average price target lagbhag ₹778.34 INR hai, jo potential upside dikhata hai. HCG apne network ko optimize karega aur patient volume badhane par focus karega.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.